Indeed, the clinical profile of patients with MMCS KIT 816+ was almost similar to that of patients with MMCS KIT 816− (Table 4) with respect to anaphylaxis (in 83% vs 73% of the patients, respectively; p = ns), skin symptoms (24% vs 48%, respectively; p = ns), neuropsychiatric symptoms (21% vs 32%, respectively; p = ns), musculoskeletal involvement (7.1% vs 28%, respectively; p = ns), malaise (3.4% vs 18%, respectively; p = ns), and asthenia (14% vs 24%, respectively; p = ns). The gene discussed is KIT; the disease is anaphylaxis.